AU2018376904B2 - FXR agonists for the treatment of liver diseases - Google Patents

FXR agonists for the treatment of liver diseases Download PDF

Info

Publication number
AU2018376904B2
AU2018376904B2 AU2018376904A AU2018376904A AU2018376904B2 AU 2018376904 B2 AU2018376904 B2 AU 2018376904B2 AU 2018376904 A AU2018376904 A AU 2018376904A AU 2018376904 A AU2018376904 A AU 2018376904A AU 2018376904 B2 AU2018376904 B2 AU 2018376904B2
Authority
AU
Australia
Prior art keywords
tropifexor
dose
nash
liver
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018376904A
Other languages
English (en)
Other versions
AU2018376904A1 (en
Inventor
Michael BADMAN
Clifford BRASS
Bryan Laffitte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018376904A1 publication Critical patent/AU2018376904A1/en
Application granted granted Critical
Publication of AU2018376904B2 publication Critical patent/AU2018376904B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018376904A 2017-11-30 2018-11-28 FXR agonists for the treatment of liver diseases Ceased AU2018376904B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593084P 2017-11-30 2017-11-30
US62/593,084 2017-11-30
PCT/IB2018/059383 WO2019106550A1 (en) 2017-11-30 2018-11-28 Fxr agonists for the treatment of liver diseases

Publications (2)

Publication Number Publication Date
AU2018376904A1 AU2018376904A1 (en) 2020-05-21
AU2018376904B2 true AU2018376904B2 (en) 2021-07-22

Family

ID=64959384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018376904A Ceased AU2018376904B2 (en) 2017-11-30 2018-11-28 FXR agonists for the treatment of liver diseases

Country Status (12)

Country Link
US (2) US20210361638A1 (https=)
EP (1) EP3716977A1 (https=)
JP (1) JP2021504370A (https=)
KR (1) KR20200094175A (https=)
CN (1) CN111356458A (https=)
AU (1) AU2018376904B2 (https=)
CA (1) CA3081656A1 (https=)
IL (1) IL274747A (https=)
MX (1) MX2020005557A (https=)
RU (1) RU2020121222A (https=)
TW (1) TW201936189A (https=)
WO (1) WO2019106550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014349A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) * 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017145041A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145031A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1734970T3 (pl) * 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
ES2862194T3 (es) * 2016-02-22 2021-10-07 Novartis Ag Métodos para usar agonistas del FXR
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017145041A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists
WO2017145031A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TULLY, D.C. et al. Journal of Medicinal Chemistry (2017) Vol.60 No.24, pages 9960 to 9973 *

Also Published As

Publication number Publication date
US20190161483A1 (en) 2019-05-30
AU2018376904A1 (en) 2020-05-21
RU2020121222A3 (https=) 2022-04-19
TW201936189A (zh) 2019-09-16
JP2021504370A (ja) 2021-02-15
CN111356458A (zh) 2020-06-30
RU2020121222A (ru) 2021-12-30
WO2019106550A1 (en) 2019-06-06
EP3716977A1 (en) 2020-10-07
MX2020005557A (es) 2020-08-20
KR20200094175A (ko) 2020-08-06
CA3081656A1 (en) 2019-06-06
US20210361638A1 (en) 2021-11-25
IL274747A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US20220313677A1 (en) Methods for treating liver disorders using fxr agonists
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
Colapietro et al. PPAR agonists for the treatment of primary biliary cholangitis: old and new tales
Hegade et al. Drug treatment of pruritus in liver diseases
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
Brodosi et al. NASH: A glance at the landscape of pharmacological treatment
TW201815420A (zh) 使用fxr促效劑之方法
AU2018376904B2 (en) FXR agonists for the treatment of liver diseases
US20200276178A1 (en) Combinations comprising fxr agonists
KR20190044667A (ko) Fxr 작용제의 신규 요법
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
JP2022548617A (ja) Ｆｘｒアゴニストを含む処置
Das et al. Bioequivalence study of antidiabetic activity between two marketed formulations of metformin on glucocorticoid-induced hyperglycemia in rabbit
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
CN117858697A (zh) Ppar激动剂和甾醇吸收抑制剂的药物组合及其用途
HK40049899A (en) Methods for using fxr agonists
HK1257647B (en) Methods for using fxr agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired